Antibody responses
[대역어] 항체 반응
[용어속성] Action
[용어속성] Action
Antibody kinetics and clinical course of COVID-19 a prospective observational study
COVID-19의 항체 역학 및 임상 경과 전향적 관찰 연구
Research Article
[키워드] analyzed
antibody
Antibody Response
Antibody responses
Antibody titer
Antibody titers
association
baseline
Clinical course
clinical manifestation
conducted
COVID-19
COVID-19 diagnosis
develop
Diagnosis
highest
hospital
Hospitalized
IgA
IgA antibodies
IgA antibody
IgG
IgG antibody
Level
levels of antibody
material
Mild disease
observational study
outcome
Pathogenesis
pathogenesis of COVID-19
Patient
patients with COVID-19
prospective observational study
response
Result
SARS-CoV-2 spike protein
severe COVID-19
severe disease
Spike protein
the spike protein
university
with mild disease
[DOI] 10.1371/journal.pone.0248918 PMC 바로가기 [Article Type] Research Article
[DOI] 10.1371/journal.pone.0248918 PMC 바로가기 [Article Type] Research Article
SARS-CoV-2 infection induces sustained humoral immune responses in convalescent patients following symptomatic COVID-19
SARS-CoV-2 감염은 증상이 있는 COVID-19 후 회복기 환자에서 체액성 면역 반응을 유도합니다
Article
[키워드] Anti-spike
antibodies
antibody
Antibody Response
Antibody responses
binding
convalescent patient
Course
COVID-19
COVID-19 disease
COVID-19 patient
detectable
disease onset
domain
humoral immune response
Humoral immunity
IgG
IgG response
IgG responses
IgM
Immunity
Immunoglobulin
immunoglobulin M
induce
large cohort
longitudinal change
longitudinal changes
magnitude
Most patients
neutralize
Neutralizing
neutralizing activities
Neutralizing activity
Neutralizing antibodies
neutralizing antibody
nucleocapsid
observation period
patients
patients with COVID-19
Protein
RBD
recognizing
recovered patient
recovered patients
response
SARS-CoV-2
SARS-COV-2 infection
SARS-CoV-2-specific antibodies
SARS-CoV-2-specific antibody
specific antibodies
specific IgM
sustained
symptomatic
symptomatic COVID-19
the SARS-CoV-2
These data
undetectable
viral infection
virus
[DOI] 10.1038/s41467-021-22034-1 PMC 바로가기 [Article Type] Article
[DOI] 10.1038/s41467-021-22034-1 PMC 바로가기 [Article Type] Article
Comorbid illnesses are associated with altered adaptive immune responses to SARS-CoV-2
동반 질환은 SARS-CoV-2에 대한 적응 면역 반응의 변화와 관련이 있습니다.
Research Article
[키워드] Adaptive immune response
Adaptive immunity
age
Analysis
antibody
Antibody Response
Antibody responses
Beta cells
breadth
CD4
Clinical outcome
Cohort
Comorbidities
convalescent
COVID-19
death
diabetes
envelope protein
envelope proteins
Ethnicity
flow cytometry
function
functional
functions
Hospitalization
Hospitalized
illness
illnesses
immune system
immunology
magnitude
nucleocapsid
obesity
reduced
risk factor
S1 domain
SARS-CoV-2
serology
severe COVID-19
Sex
subject
subjects
symptom onset
T cell
T cells
These data
[DOI] 10.1172/jci.insight.146242 PMC 바로가기 [Article Type] Research Article
[DOI] 10.1172/jci.insight.146242 PMC 바로가기 [Article Type] Research Article
Association of Age With SARS-CoV-2 Antibody Response
SARS-CoV-2 항체 반응과 연령의 연관성
Research
[키워드] 95% CI
acute respiratory syndrome
acute respiratory syndrome coronavirus
acute respiratory syndrome coronavirus 2
addition
Adolescent
adolescents and adults
Adults
age
Analysis
antibody
Antibody binding
Antibody Response
Antibody responses
Antibody test
antibody test result
antibody tests
association
avidity
children
Cohort
collected
coronavirus
correlated
cross-sectional
cross-sectional study
disease
evaluated
Evidence
exhibited
Female patients
finding
group
groups
hospital
IgG
IgG level
IgG levels
immune response
Importance
IQR
lower risk
lowest
management
measure
median
Mild symptom
mild symptoms
moderate
negative correlation
Neutralizing activity
neutralizing antibody
New York City
not significant
objective
participant
Patient
patient population
patients
pediatric
Pediatric patient
performed
Point
populations
positive correlation
profile
quantity
relative fluorescence unit
relative fluorescence units
Relevance
Respiratory disease
response
responses
Result
RFU
SARS-CoV-2
SARS-CoV-2 antibody
SARS-CoV-2 antibody responses
SARS-CoV-2 antibody test
SARS-CoV-2 antibody tests
SARS-CoV-2 IgG
SARS-CoV-2 viral
sera
Seroprevalence
setting
severe acute respiratory syndrome Coronavirus
severe acute respiratory syndrome coronavirus 2
severe respiratory disease
SNAb
subset
Vaccine development
was performed
[DOI] 10.1001/jamanetworkopen.2021.4302 PMC 바로가기 [Article Type] Research
[DOI] 10.1001/jamanetworkopen.2021.4302 PMC 바로가기 [Article Type] Research
Longitudinal Profiling of Antibody Response in Patients With COVID-19 in a Tertiary Care Hospital in Beijing, China
중국 베이징의 3차 진료 병원에서 COVID-19 환자의 항체 반응에 대한 종단 프로파일링
Immunology
[키워드] acute respiratory syndrome
acute respiratory syndrome coronavirus
acute respiratory syndrome coronavirus 2
Analysis
anti-RBD
antibody
Antibody Response
Antibody responses
antibody-based therapies
antigens
association
asymptomatic patient
asymptomatic patients
Beijing
C-reactive protein
caused
changed
changes in
China
complement
contribute
coronavirus
coronavirus disease
Coronavirus disease 2019
COVID-19
death
Diagnosis
diagnostic
disease onset
elicit
global pandemic
humoral immune response
IgM and IgG
indicated
inflammatory cell
inflammatory cells
investigated
knowledge
lead
longitudinal
majority
Mild
moderate
Neutralizing antibodies
neutralizing antibody
Novel coronavirus
onset of symptoms
Pairwise comparison
Patient
patients with COVID-19
plasma sample
plasma samples
populations
Profiling
RBD
reached
Real-time PCR
respiratory
response
S antigen
SARS-CoV-2
SARS-COV-2 infection
Seroconversion
serological test
Serological tests
Seroprevalence
severe acute respiratory syndrome Coronavirus
severe cases
Sex
significantly
specific antibodies
spike
Surveillance
Symptoms
Tertiary
the antibody response
the disease
undetectable
Vaccine
variety
Viral
Viral load
virus-specific antibodies
[DOI] 10.3389/fimmu.2021.614436 PMC 바로가기 [Article Type] Immunology
[DOI] 10.3389/fimmu.2021.614436 PMC 바로가기 [Article Type] Immunology
Antibody isotype diversity against SARS-CoV-2 is associated with differential serum neutralization capacities
SARS-CoV-2에 대한 항체 동형 다양성은 차등 혈청 중화 능력과 관련이 있습니다
Article
[키워드] addressed
Analysis
antibodies
antibody
antibody isotype
antibody isotypes
Antibody Response
Antibody responses
antigens
authentic SARS-CoV-2 virus
can be used
Cohort
Containment measure
containment measures
contribute
convalescent patient
Convalescent patients
COVID-19 pandemic
cross
ELISA
Evidence
healthcare worker
IgA antibodies
IgA antibody
IgG
IgM
individual
majority
neutralization
neutralization capacity
Neutralizing
Neutralizing antibody response
Neutralizing titer
nucleoprotein
overcome
performed
positive
predict
preliminary evidence
provide
Pseudotyped virus
recent
Receptor binding domain
SARS-CoV-2
SARS-CoV-2 antibody
SARS-CoV-2 neutralization
SARS-CoV-2 virus
sera
serum
serum IgG
Serum Neutralization
spike
Still
sustained
the SARS-CoV-2
the Spike
understanding
[DOI] 10.1038/s41598-021-84913-3 PMC 바로가기 [Article Type] Article
[DOI] 10.1038/s41598-021-84913-3 PMC 바로가기 [Article Type] Article
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials
단회 투여 및 ChAdOx1 nCoV-19(AZD1222) 백신의 면역원성 및 효능에 대한 추가 투여 시간의 영향: 4건의 무작위 시험에 대한 통합 분석
Meta-Analysis
[키워드] 1:1
95% CI
addition
administration
Ageusia
All participants
Analysis
Anosmia
antibody
antibody levels
Antibody Response
Antibody responses
approved
assigned
AstraZeneca
AZD1222
baseline
binding antibody
booster dose
booster doses
Brazil
category
ChAdOx1
ChAdOx1 nCoV-19
Clinical research
Coalition
control group
control vaccine
cough
COV005
COVID-19
COVID-19 disease
COVID-19-related death
Cutoff
death
defined
described
dose
doses
double-blind
Efficacy
Emergency use
Endpoint
Evidence
evidence of
exclusion
exploratory
Exploratory analyses
Exploratory analysis
Fever
finding
first dose
FIVE
Follow-up
for inclusion
foundation
funding
geometric mean
geometric mean ratio
GMR
had no
Hospital admission
immunoassay
immunogenicity
immunogenicity data
independent
indicated
individual
Infection
initial
Innovation
interim analysis
ISRCTN89951424
less
lower dose
Medicine
Medicines
Medicines and Healthcare products Regulatory Agency
Melinda Gate
Melinda Gates
N protein
NAAT
NAAT-positive swab
network
neutralisation
NIHR
no evidence of
nucleic acid
nucleic acid amplification
nucleic acid amplification test
observation
offered
Older
outcomes
Oxford
pandemic
participant
phase 2/3
phase 3 study
positive swab
primary analysis
primary endpoint
Primary outcome
prime-boost interval
priming
PROTECT
pseudovirus
randomised controlled
Randomised trial
Randomly
receive
receiving
recruited
regimen
Registered
regulatory authority
response
Safety
saline placebo
SARS-COV-2 infection
SARS-CoV-2 N protein
second dose
secondary
Serious Adverse Events
seronegative
Seven
Shortness of breath
single-blind
Single-dose
South
South Africa
Standard dose
subset
supported
Swab
swabs
Symptom
symptomatic COVID-19 disease
symptomatic infection
Telle
the primary endpoint
the timing
the vaccine
Trial
vaccination
Vaccine
vaccine efficacy
Valley
Viral
Viral particles
[DOI] 10.1016/S0140-6736(21)00432-3 PMC 바로가기 [Article Type] Meta-Analysis
[DOI] 10.1016/S0140-6736(21)00432-3 PMC 바로가기 [Article Type] Meta-Analysis
The effect of spike mutations on SARS-CoV-2 neutralization
SARS-CoV-2 중화에 대한 스파이크 돌연변이의 영향
Report
[키워드] Abstract
active against
acute respiratory syndrome
acute respiratory syndrome coronavirus
Alter
Amino acid
amino acid changes
amino acid substitution
amino acids
antibodies
antibody
Antibody Response
Antibody responses
B.1.1.7
B.1.1.7 variant
B.1.351
change
changes in
collected
convalescent sera
coronavirus
Critical
decrease
Divergence
effective
Efficacy
ENCODE
evaluate
highlight
Immune escape
individual
Infection
less
lineages
mild illness
monoclonal antibody
Multiple
mutants
mutated
Mutation
mutations
neutralization
Neutralizing antibodies
neutralizing antibody
new SARS-CoV-2
P.1
polyclonal antibodies
polyclonal antibody
potency
produced
Protective
Protein
pseudotype
Pseudotyped virus
Real-time monitoring
recognizing
reduced
respiratory
SARS-CoV
SARS-CoV-2
SARS-CoV-2 neutralization
SARS-CoV-2 pseudotyped virus
SARS-CoV-2 spike
SARS-CoV-2 variants
SARS-CoV-2 virus
sensitivity
sera
serology
serum sample
serum samples
severe acute respiratory syndrome Coronavirus
spike mutation
Substitution
Vaccine
vaccine efficacy
variant
variant spike
Variation
Viral
viral entry
[DOI] 10.1016/j.celrep.2021.108890 PMC 바로가기 [Article Type] Report
[DOI] 10.1016/j.celrep.2021.108890 PMC 바로가기 [Article Type] Report
Immune response following infection with SARS-CoV-2 and other coronaviruses: A rapid review
SARS-CoV-2 및 기타 코로나바이러스 감염 후 면역 반응: 신속한 검토
Review
[키워드] antibody
Antibody Response
Antibody responses
COVID-19
database
databases
Decline
declined
Evidence
Follow-up
IgG
IgM and IgG
immune response
inclusion criteria
infection with SARS-CoV-2
MERS
MERS-CoV
methodology
Most patients
Neutralizing antibodies
Patient
Post-infection
protocol
Reinfection
reported
responses
retrieved
RNA
SARS-CoV
SARS-CoV-2
SARS-COV-2 infection
SARS-CoV-2-specific IgG
searched
seasonal coronaviruses
Seroconversion
seroconvert
seroconverted
sustained
while
[DOI] 10.1002/rmv.2162 PMC 바로가기 [Article Type] Review
[DOI] 10.1002/rmv.2162 PMC 바로가기 [Article Type] Review